levodopa ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors 1567 59-92-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • levodopa
  • ledopa
  • 3-Hydroxy-L-tyrosine
  • DOPA
  • dihydroxyphenylalanine
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
  • Molecular weight: 197.19
  • Formula: C9H11NO4
  • CLOGP: -2.82
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 103.78
  • ALOGS: -1.78
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3.50 g O
0.60 g O
0.45 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 66 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 674.47 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 41 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 23 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.76 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K2,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,SRC,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 79
kinase-selectivity-class ACVR2B,AXL,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PRKDC,STK33,SYK,TEK,TGFBR1 16
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Sept. 19, 2019 EMA Acorda Therapeutics Ireland Limited
June 4, 1970 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 539.64 15.87 205 13718 36329 90578195
On and off phenomenon 273.10 15.87 66 13857 2477 90612047
Hallucination 259.67 15.87 148 13775 65811 90548713
Muscle rigidity 228.12 15.87 85 13838 14224 90600300
Hallucination, visual 201.60 15.87 89 13834 23003 90591521
Parkinson's disease 184.75 15.87 41 13882 1049 90613475
Freezing phenomenon 159.04 15.87 40 13883 1772 90612752
Tremor 146.40 15.87 147 13776 153026 90461498
Impulse-control disorder 144.99 15.87 33 13890 949 90613575
Bradykinesia 136.93 15.87 48 13875 6740 90607784
Myoclonus 133.05 15.87 63 13860 19105 90595419
Neuroleptic malignant syndrome 127.93 15.87 57 13866 15039 90599485
Dystonia 112.82 15.87 54 13869 16765 90597759
Dementia 108.71 15.87 59 13864 23802 90590722
Delusion 100.70 15.87 47 13876 13793 90600731
Pleurothotonus 100.13 15.87 26 13897 1309 90613215
Fall 98.87 15.87 224 13699 481586 90132938
Speech disorder 98.30 15.87 70 13853 45515 90569009
Stoma site discharge 89.87 15.87 26 13897 1963 90612561
Compulsive shopping 87.92 15.87 21 13902 748 90613776
Stoma site erythema 83.19 15.87 23 13900 1473 90613051
Vascular encephalopathy 82.74 15.87 20 13903 750 90613774
Dopamine dysregulation syndrome 78.99 15.87 15 13908 171 90614353
Parkinsonism 78.95 15.87 40 13883 14025 90600499
Sudden onset of sleep 77.50 15.87 18 13905 567 90613957
Stereotypy 76.44 15.87 17 13906 439 90614085
Delirium 74.67 15.87 86 13837 104273 90510251
Ileus 72.83 15.87 40 13883 16506 90598018
Akinesia 70.97 15.87 21 13902 1715 90612809
Choking 63.99 15.87 33 13890 12000 90602524
Gambling disorder 63.90 15.87 18 13905 1234 90613290
Abnormal behaviour 61.24 15.87 40 13883 22588 90591936
Hyperkinesia 60.46 15.87 19 13904 1900 90612624
Stoma site reaction 59.36 15.87 13 13910 312 90614212
Fibroma 58.88 15.87 16 13907 960 90613564
Spinal cord haematoma 57.92 15.87 12 13911 219 90614305
Orthostatic hypotension 57.04 15.87 49 13874 41778 90572746
Dropped head syndrome 56.28 15.87 12 13911 253 90614271
Joint swelling 56.17 15.87 6 13917 503294 90111230
Product residue present 55.85 15.87 22 13901 4269 90610255
Torticollis 55.10 15.87 19 13904 2539 90611985
Drug interaction 54.84 15.87 127 13796 276326 90338198
Stoma site irritation 52.82 15.87 12 13911 342 90614182
Camptocormia 49.54 15.87 11 13912 282 90614242
Rash 49.06 15.87 31 13892 796069 89818455
Subileus 48.54 15.87 19 13904 3625 90610899
Peripheral swelling 48.54 15.87 4 13919 413102 90201422
Gait disturbance 47.68 15.87 116 13807 260380 90354144
Product complaint 46.98 15.87 28 13895 13472 90601052
Posture abnormal 46.48 15.87 17 13906 2694 90611830
Somnolence 45.85 15.87 100 13823 208984 90405540
Dysphagia 45.40 15.87 70 13853 112208 90502316
Disorientation 45.14 15.87 44 13879 44070 90570454
Gastrointestinal sounds abnormal 44.49 15.87 19 13904 4524 90610000
Reduced facial expression 43.74 15.87 16 13907 2537 90611987
Psychotic disorder 43.42 15.87 37 13886 31193 90583331
Therapeutic product effect variable 43.38 15.87 14 13909 1525 90612999
Hypokinesia 40.65 15.87 27 13896 15670 90598854
Stoma site pain 40.39 15.87 13 13910 1404 90613120
Faecaloma 39.89 15.87 23 13900 10408 90604116
Device issue 39.04 15.87 34 13889 29503 90585021
Gaze palsy 38.52 15.87 13 13910 1628 90612896
Alopecia 38.50 15.87 14 13909 495057 90119467
Hepatic enzyme increased 38.48 15.87 5 13918 360731 90253793
Glossodynia 38.11 15.87 3 13920 321776 90292748
Jealous delusion 38.07 15.87 7 13916 66 90614458
Contraindicated product administered 37.87 15.87 3 13920 320136 90294388
Drug withdrawal syndrome 37.84 15.87 33 13890 28690 90585834
Aortic valve incompetence 37.64 15.87 19 13904 6605 90607919
Cognitive disorder 36.44 15.87 49 13874 69358 90545166
Abdominal discomfort 36.28 15.87 14 13909 477314 90137210
Agitation 36.20 15.87 48 13875 67050 90547474
Movement disorder 35.56 15.87 32 13891 28987 90585537
Restlessness 35.37 15.87 35 13888 35685 90578839
Pruritus 34.83 15.87 20 13903 541505 90073019
Tension 34.74 15.87 15 13908 3667 90610857
Drug hypersensitivity 32.97 15.87 15 13908 463594 90150930
Paranoia 32.94 15.87 22 13901 12886 90601638
Tarsal tunnel syndrome 32.68 15.87 9 13914 568 90613956
Hypersensitivity 31.89 15.87 15 13908 454662 90159862
Aggression 31.87 15.87 29 13894 26639 90587885
Abdominal tenderness 31.56 15.87 19 13904 9305 90605219
Blood creatine phosphokinase increased 31.23 15.87 32 13891 33991 90580533
Device difficult to use 31.21 15.87 24 13899 17501 90597023
Deep brain stimulation 30.87 15.87 6 13917 78 90614446
Arthropathy 30.85 15.87 9 13914 366233 90248291
Nasopharyngitis 30.82 15.87 12 13911 407092 90207432
Wound 30.45 15.87 5 13918 302975 90311549
Depressed level of consciousness 30.29 15.87 46 13877 72738 90541786
Ketonuria 29.98 15.87 9 13914 772 90613752
Parkinsonism hyperpyrexia syndrome 29.71 15.87 7 13916 235 90614289
Dysarthria 29.42 15.87 39 13884 54443 90560081
Headache 29.38 15.87 55 13868 862691 89751833
Hallucination, auditory 28.72 15.87 22 13901 15953 90598571
Heat stroke 28.68 15.87 9 13914 895 90613629
Cerebral atrophy 28.63 15.87 15 13908 5631 90608893
Rheumatoid arthritis 28.61 15.87 10 13913 362604 90251920
Lower respiratory tract infection 27.90 15.87 3 13920 250656 90363868
Oromandibular dystonia 27.76 15.87 8 13915 595 90613929
Urticaria 27.62 15.87 7 13916 312727 90301797
Purpura senile 27.61 15.87 8 13915 607 90613917
Coma 27.57 15.87 44 13879 72588 90541936
Eczema eyelids 26.98 15.87 7 13916 351 90614173
Wrong product administered 26.93 15.87 16 13907 7649 90606875
Diarrhoea 26.89 15.87 66 13857 939124 89675400
Infection 26.87 15.87 11 13912 362083 90252441
Stomatitis 26.59 15.87 5 13918 274693 90339831
Resorption bone increased 26.04 15.87 9 13914 1210 90613314
Abnormal dreams 25.91 15.87 18 13905 11239 90603285
Balance disorder 25.44 15.87 50 13873 97030 90517494
Device use issue 25.13 15.87 12 13911 3701 90610823
Catatonia 24.89 15.87 14 13909 6042 90608482
Swelling 24.82 15.87 17 13906 419041 90195483
Resting tremor 24.76 15.87 8 13915 875 90613649
Rib fracture 24.51 15.87 25 13898 26410 90588114
Device occlusion 24.12 15.87 16 13907 9266 90605258
Vestibular disorder 23.94 15.87 9 13914 1540 90612984
Blister 23.92 15.87 5 13918 254993 90359531
Exposure during pregnancy 23.81 15.87 4 13919 238406 90376118
Pain 23.37 15.87 77 13846 996264 89618260
Pneumonia aspiration 23.18 15.87 30 13893 40910 90573614
Loss of consciousness 23.05 15.87 60 13863 140178 90474346
Aspiration 22.65 15.87 19 13904 15674 90598850
Retroperitoneal fibrosis 22.45 15.87 6 13917 338 90614186
Syncope 22.05 15.87 57 13866 132606 90481918
Bladder disorder 21.96 15.87 16 13907 10756 90603768
Bradyphrenia 21.93 15.87 14 13909 7598 90606926
Stoma site inflammation 21.65 15.87 7 13916 767 90613757
Fibromyalgia 21.65 15.87 3 13920 206266 90408258
Orthostatic intolerance 21.41 15.87 8 13915 1346 90613178
Hypophagia 21.39 15.87 27 13896 35910 90578614
Stoma site hypergranulation 21.36 15.87 6 13917 407 90614117
Periorbital haematoma 21.33 15.87 7 13916 804 90613720
Cogwheel rigidity 21.27 15.87 9 13914 2093 90612431
Confusional state 21.22 15.87 116 13807 386089 90228435
Application site reaction 21.17 15.87 7 13916 823 90613701
Product administration error 20.97 15.87 23 13900 26400 90588124
Saliva discolouration 20.87 15.87 4 13919 48 90614476
Anxiety 20.47 15.87 98 13825 309674 90304850
Withdrawal syndrome 20.34 15.87 21 13902 22503 90592021
Coronary artery dissection 20.21 15.87 7 13916 947 90613577
Stoma site odour 19.36 15.87 4 13919 72 90614452
Feeling abnormal 19.25 15.87 63 13860 167172 90447352
Parkinsonian gait 19.23 15.87 6 13917 586 90613938
Labelled drug-disease interaction issue 19.20 15.87 4 13919 75 90614449
Yawning 19.16 15.87 7 13916 1105 90613419
Ammonia increased 19.08 15.87 11 13912 4975 90609549
Wrong technique in product usage process 18.92 15.87 37 13886 71534 90542990
Hypersexuality 18.90 15.87 6 13917 620 90613904
Intentional product use issue 18.87 15.87 5 13918 216887 90397637
Cross sensitivity reaction 18.63 15.87 9 13914 2848 90611676
Asthma 18.54 15.87 7 13916 242153 90372371
Renal failure 18.48 15.87 53 13870 130954 90483570
Therapeutic response shortened 18.30 15.87 20 13903 22859 90591665
Rhabdomyolysis 18.02 15.87 30 13893 51226 90563298
Endocarditis 17.85 15.87 12 13911 7101 90607423
Nuchal rigidity 17.65 15.87 6 13917 768 90613756
Device kink 17.60 15.87 8 13915 2207 90612317
Urinary tract infection 17.59 15.87 93 13830 305539 90308985
Product use issue 17.47 15.87 15 13908 329904 90284620
Erysipelas 17.45 15.87 13 13910 9039 90605485
Psychomotor hyperactivity 17.44 15.87 15 13908 12798 90601726
Obsessive-compulsive disorder 17.40 15.87 10 13913 4494 90610030
Polyneuropathy 17.40 15.87 18 13905 19323 90595201
Delusion of parasitosis 17.13 15.87 4 13919 129 90614395
Treatment failure 17.11 15.87 13 13910 303915 90310609
White blood cell count increased 16.86 15.87 34 13889 67207 90547317
Dementia with Lewy bodies 16.69 15.87 5 13918 426 90614098
Blood chloride decreased 16.68 15.87 11 13912 6308 90608216
Wheezing 16.45 15.87 8 13915 238072 90376452
Kleptomania 16.44 15.87 3 13920 27 90614497
Impaired healing 15.98 15.87 8 13915 234191 90380333
Progressive supranuclear palsy 15.95 15.87 4 13919 175 90614349
Urinary retention 15.90 15.87 24 13899 37720 90576804
Acute myocardial infarction 15.87 15.87 23 13900 34867 90579657

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 475.26 16.40 211 14154 25179 42581791
On and off phenomenon 382.42 16.40 108 14257 3359 42603611
Gambling disorder 357.03 16.40 89 14276 1687 42605283
Dopamine dysregulation syndrome 307.75 16.40 64 14301 509 42606461
Hallucination 303.87 16.40 207 14158 57300 42549670
Hypersexuality 271.86 16.40 71 14294 1631 42605339
Impulse-control disorder 243.37 16.40 64 14301 1511 42605459
Muscle rigidity 234.35 16.40 103 14262 11956 42595014
Parkinson's disease 210.42 16.40 55 14310 1267 42605703
Hallucination, visual 164.20 16.40 97 14268 20923 42586047
Fall 152.06 16.40 278 14087 234242 42372728
Neuroleptic malignant syndrome 139.30 16.40 88 14277 21384 42585586
Freezing phenomenon 134.64 16.40 42 14323 1847 42605123
Bradykinesia 127.26 16.40 53 14312 5383 42601587
Akinesia 119.63 16.40 41 14324 2431 42604539
Tremor 102.71 16.40 144 14221 96785 42510185
Gambling 92.78 16.40 20 14345 192 42606778
Sudden onset of sleep 84.96 16.40 21 14344 383 42606587
Delusion 84.73 16.40 56 14309 14678 42592292
Dementia 83.71 16.40 58 14307 16422 42590548
Gait disturbance 81.48 16.40 130 14235 97870 42509100
Confusional state 81.01 16.40 176 14189 167421 42439549
Parkinsonism 75.09 16.40 46 14319 10577 42596393
Compulsive shopping 72.49 16.40 19 14346 442 42606528
Psychotic disorder 71.45 16.40 67 14298 29141 42577829
Abnormal behaviour 71.17 16.40 64 14301 26387 42580583
Orthostatic hypotension 70.74 16.40 68 14297 30502 42576468
Therapeutic product effect variable 68.37 16.40 29 14336 3080 42603890
Dystonia 67.28 16.40 46 14319 12744 42594226
Agitation 62.84 16.40 92 14273 64222 42542748
Dysphagia 62.52 16.40 98 14267 72621 42534349
Stoma site discharge 61.88 16.40 22 14343 1454 42605516
Delirium 61.56 16.40 82 14283 52437 42554533
Reduced facial expression 61.06 16.40 22 14343 1511 42605459
Jealous delusion 55.35 16.40 15 14350 398 42606572
Obsessive-compulsive disorder 54.94 16.40 32 14333 6711 42600259
Aggression 53.36 16.40 70 14295 44093 42562877
Paraphilia 52.71 16.40 11 14354 89 42606881
Diarrhoea 51.36 16.40 48 14317 460801 42146169
Off label use 49.95 16.40 87 14278 638248 41968722
Stoma site erythema 49.83 16.40 17 14348 993 42605977
Saliva discolouration 49.55 16.40 9 14356 31 42606939
Restlessness 49.48 16.40 55 14310 29194 42577776
Cognitive disorder 48.98 16.40 59 14306 34113 42572857
Febrile neutropenia 47.71 16.40 4 14361 185699 42421271
Hyperkinesia 47.57 16.40 20 14345 2078 42604892
Device use issue 46.38 16.40 16 14349 967 42606003
Binge eating 42.54 16.40 10 14355 146 42606824
Fibroma 41.57 16.40 12 14353 403 42606567
Mobility decreased 41.16 16.40 55 14310 35251 42571719
Posture abnormal 40.90 16.40 19 14346 2502 42604468
Device dislocation 40.79 16.40 28 14337 7803 42599167
Speech disorder 39.66 16.40 49 14316 29072 42577898
Phlebitis infective 38.97 16.40 9 14356 121 42606849
Device issue 38.94 16.40 34 14331 13475 42593495
Somnolence 36.96 16.40 118 14247 140987 42465983
Product cleaning inadequate 36.89 16.40 6 14359 8 42606962
Embedded device 36.47 16.40 11 14354 431 42606539
Pleurothotonus 35.91 16.40 14 14351 1197 42605773
Abnormal dreams 34.86 16.40 26 14339 8245 42598725
Compulsions 33.27 16.40 9 14356 237 42606733
Postural reflex impairment 32.74 16.40 6 14359 22 42606948
Impulsive behaviour 32.41 16.40 16 14349 2409 42604561
Compulsive sexual behaviour 32.15 16.40 9 14356 270 42606700
Persecutory delusion 31.94 16.40 18 14347 3546 42603424
Obsessive-compulsive personality disorder 31.86 16.40 8 14357 156 42606814
Deep brain stimulation 31.76 16.40 6 14359 27 42606943
Balance disorder 31.33 16.40 57 14308 47588 42559382
Disorientation 31.18 16.40 49 14316 36340 42570630
Neutropenia 29.81 16.40 15 14350 199416 42407554
Stereotypy 29.52 16.40 11 14354 831 42606139
Tension 29.25 16.40 15 14350 2449 42604521
Pruritus 28.51 16.40 14 14351 188757 42418213
Marital problem 27.98 16.40 6 14359 56 42606914
Libido increased 27.92 16.40 11 14354 967 42606003
Device difficult to use 27.71 16.40 18 14347 4578 42602392
Sleep attacks 27.61 16.40 7 14358 142 42606828
Therapeutic response shortened 27.35 16.40 28 14337 13526 42593444
Depression 27.23 16.40 91 14274 111272 42495698
Movement disorder 27.22 16.40 29 14336 14669 42592301
Pneumonia aspiration 26.90 16.40 55 14310 50023 42556947
Stoma site irritation 26.58 16.40 7 14358 166 42606804
Platelet count decreased 26.48 16.40 7 14358 138574 42468396
Hypertonia 26.32 16.40 18 14347 4983 42601987
Camptocormia 26.00 16.40 7 14358 181 42606789
Apathy 25.94 16.40 22 14343 8384 42598586
Product complaint 25.66 16.40 19 14346 5958 42601012
Parkinsonian gait 25.63 16.40 9 14356 573 42606397
Wrong technique in device usage process 24.91 16.40 14 14351 2743 42604227
Product residue present 24.52 16.40 14 14351 2827 42604143
Motor dysfunction 24.48 16.40 21 14344 8125 42598845
Memory impairment 24.47 16.40 53 14312 50169 42556801
Aortic valve incompetence 24.12 16.40 19 14346 6529 42600441
Syncope 24.09 16.40 81 14284 99325 42507645
Progressive supranuclear palsy 23.01 16.40 5 14360 50 42606920
Product packaging difficult to open 22.98 16.40 4 14361 10 42606960
Stoma site inflammation 22.54 16.40 8 14357 526 42606444
Serotonin syndrome 22.41 16.40 35 14330 25810 42581160
Hyperthermia 21.87 16.40 24 14341 12550 42594420
Mania 21.67 16.40 22 14343 10525 42596445
Malignant neoplasm progression 21.63 16.40 5 14360 108395 42498575
Pyrexia 21.53 16.40 65 14300 393977 42212993
Supine hypertension 21.05 16.40 7 14358 378 42606592
Autonomic nervous system imbalance 20.76 16.40 13 14352 3103 42603867
Illusion 20.66 16.40 9 14356 1020 42605950
Pancytopenia 20.58 16.40 7 14358 117736 42489234
Diastolic hypotension 20.44 16.40 6 14359 214 42606756
Device occlusion 19.92 16.40 19 14346 8431 42598539
Product use in unapproved indication 19.55 16.40 20 14345 184436 42422534
Arthralgia 18.80 16.40 25 14340 205213 42401757
Choking 18.45 16.40 16 14349 6282 42600688
Drug withdrawal syndrome 18.43 16.40 29 14336 21520 42585450
Extrapyramidal disorder 18.26 16.40 25 14340 16387 42590583
Anxiety 17.70 16.40 83 14282 118477 42488493
Micrographia 17.69 16.40 3 14362 6 42606964
Psychomotor hyperactivity 17.49 16.40 20 14345 10938 42596032
Formication 17.46 16.40 10 14355 2031 42604939
Blood creatine phosphokinase increased 17.04 16.40 45 14320 48293 42558677
Anticholinergic syndrome 16.93 16.40 9 14356 1580 42605390
Hyperreflexia 16.70 16.40 12 14353 3595 42603375
Mesenteric artery thrombosis 16.65 16.40 7 14358 727 42606243
Paranoia 16.57 16.40 22 14343 14004 42592966

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 782.64 14.95 315 21271 51131 110516582
On and off phenomenon 493.13 14.95 124 21462 4300 110563413
Hallucination 446.25 14.95 266 21320 101166 110466547
Muscle rigidity 371.47 14.95 149 21437 23882 110543831
Dopamine dysregulation syndrome 355.68 14.95 67 21519 560 110567153
Impulse-control disorder 333.75 14.95 79 21507 2115 110565598
Hallucination, visual 320.97 14.95 156 21430 39449 110528264
Gambling disorder 302.76 14.95 73 21513 2118 110565595
Parkinson's disease 284.91 14.95 65 21521 1474 110566239
Neuroleptic malignant syndrome 278.51 14.95 135 21451 33924 110533789
Hypersexuality 259.67 14.95 63 21523 1877 110565836
Bradykinesia 209.60 14.95 79 21507 10709 110557004
Tremor 181.16 14.95 210 21376 202022 110365691
Akinesia 180.25 14.95 54 21532 3613 110564100
Dystonia 174.68 14.95 90 21496 25715 110541998
Dementia 170.92 14.95 95 21491 31578 110536135
Fall 167.02 14.95 365 21221 603117 109964596
Delusion 167.02 14.95 85 21501 23670 110544043
Freezing phenomenon 161.72 14.95 46 21540 2563 110565150
Parkinsonism 146.19 14.95 76 21510 22111 110545602
Pleurothotonus 132.41 14.95 39 21547 2459 110565254
Compulsive shopping 125.49 14.95 30 21556 838 110566875
Myoclonus 118.13 14.95 76 21510 32922 110534791
Abnormal behaviour 108.83 14.95 77 21509 38962 110528751
Agitation 105.50 14.95 120 21466 112931 110454782
Orthostatic hypotension 101.59 14.95 92 21494 66157 110501556
Speech disorder 101.36 14.95 89 21497 61480 110506233
Delirium 100.88 14.95 128 21458 134897 110432816
Therapeutic product effect variable 95.66 14.95 31 21555 2687 110565026
Reduced facial expression 90.48 14.95 32 21554 3619 110564094
Sudden onset of sleep 89.69 14.95 22 21564 686 110567027
Hyperkinesia 86.95 14.95 30 21556 3154 110564559
Aggression 84.51 14.95 79 21507 59131 110508582
Gait disturbance 84.43 14.95 175 21411 278033 110289680
Psychotic disorder 82.57 14.95 73 21513 50864 110516849
Gambling 81.31 14.95 18 21568 354 110567359
Vascular encephalopathy 76.63 14.95 20 21566 804 110566909
Torticollis 75.16 14.95 27 21559 3194 110564519
Stereotypy 72.46 14.95 20 21566 997 110566716
Camptocormia 71.24 14.95 17 21569 471 110567242
Confusional state 69.39 14.95 225 21361 468455 110099258
Dysphagia 68.41 14.95 114 21472 153486 110414227
Stoma site discharge 67.37 14.95 24 21562 2771 110564942
Posture abnormal 66.75 14.95 27 21559 4411 110563302
Jealous delusion 66.58 14.95 16 21570 457 110567256
Diarrhoea 65.31 14.95 76 21510 1139429 109428284
Drug interaction 65.12 14.95 230 21356 499953 110067760
Somnolence 64.62 14.95 164 21422 297285 110270428
Drug withdrawal syndrome 62.60 14.95 55 21531 37999 110529714
Aortic valve incompetence 62.14 14.95 34 21552 10947 110556766
Ileus 62.07 14.95 50 21536 30679 110537034
Restlessness 61.63 14.95 65 21521 56194 110511519
Cognitive disorder 60.70 14.95 80 21506 87431 110480282
Disorientation 57.56 14.95 70 21516 70601 110497112
Binge eating 57.19 14.95 15 21571 615 110567098
Joint swelling 55.01 14.95 10 21576 442835 110124878
Pneumonia aspiration 54.40 14.95 73 21513 81160 110486553
Paraphilia 53.92 14.95 10 21576 76 110567637
Deep brain stimulation 53.80 14.95 10 21576 77 110567636
Peripheral swelling 52.67 14.95 8 21578 404026 110163687
Blood creatine phosphokinase increased 52.53 14.95 68 21518 73009 110494704
Pruritus 47.91 14.95 27 21559 581533 109986180
Device use issue 46.72 14.95 20 21566 3764 110563949
Stoma site erythema 46.61 14.95 17 21569 2100 110565613
Abdominal discomfort 46.59 14.95 10 21576 393848 110173865
Sinusitis 46.10 14.95 3 21583 296685 110271028
Alopecia 45.80 14.95 8 21578 364745 110202968
Persecutory delusion 45.63 14.95 23 21563 6268 110561445
Obsessive-compulsive disorder 45.40 14.95 24 21562 7217 110560496
Urticaria 44.71 14.95 5 21581 318852 110248861
Drug hypersensitivity 43.68 14.95 17 21569 454073 110113640
Rash 43.55 14.95 58 21528 820906 109746807
Therapeutic response shortened 43.22 14.95 40 21546 29543 110538170
Product residue present 42.71 14.95 19 21567 3922 110563791
Postural reflex impairment 42.16 14.95 7 21579 25 110567688
Fibroma 41.38 14.95 13 21573 1019 110566694
Stoma site pain 40.40 14.95 15 21571 1948 110565765
Hepatic enzyme increased 40.37 14.95 7 21579 320885 110246828
Dropped head syndrome 40.07 14.95 11 21575 537 110567176
Product complaint 39.95 14.95 28 21558 13944 110553769
Movement disorder 39.76 14.95 42 21544 36362 110531351
Subileus 39.41 14.95 21 21565 6416 110561297
Impulsive behaviour 39.22 14.95 17 21569 3298 110564415
Parkinsonism hyperpyrexia syndrome 38.77 14.95 11 21575 607 110567106
Off label use 38.39 14.95 157 21429 1500028 109067685
Faecaloma 38.32 14.95 28 21558 14880 110552833
Cerebral atrophy 37.73 14.95 23 21563 9062 110558651
Febrile neutropenia 37.54 14.95 8 21578 316759 110250954
Pain 37.32 14.95 82 21504 954873 109612840
Dysarthria 36.85 14.95 62 21524 84059 110483654
Hypokinesia 36.80 14.95 32 21554 21794 110545919
Device issue 36.22 14.95 39 21547 34496 110533217
Paranoia 36.12 14.95 32 21554 22342 110545371
Syncope 35.26 14.95 103 21483 202433 110365280
Gastrointestinal sounds abnormal 35.07 14.95 19 21567 5999 110561714
Serotonin syndrome 34.86 14.95 50 21536 59103 110508610
Rheumatoid arthritis 34.63 14.95 8 21578 299605 110268108
Tricuspid valve incompetence 34.33 14.95 32 21554 23841 110543872
Swelling 33.98 14.95 13 21573 351028 110216685
Withdrawal syndrome 33.91 14.95 36 21550 31344 110536369
Progressive supranuclear palsy 33.72 14.95 8 21578 216 110567497
Compulsions 33.37 14.95 9 21577 411 110567302
Dementia with Lewy bodies 32.86 14.95 11 21575 1055 110566658
Product cleaning inadequate 32.22 14.95 5 21581 10 110567703
Contraindicated product administered 32.15 14.95 5 21581 248262 110319451
Apathy 31.90 14.95 26 21560 16213 110551500
Headache 31.86 14.95 79 21507 882298 109685415
Pericarditis 31.83 14.95 3 21583 219111 110348602
Stomatitis 31.66 14.95 7 21579 270235 110297478
Hypertonia 31.66 14.95 20 21566 8386 110559327
Oromandibular dystonia 31.41 14.95 11 21575 1208 110566505
Lower respiratory tract infection 31.24 14.95 5 21581 243101 110324612
Resting tremor 31.24 14.95 12 21574 1711 110566002
Tarsal tunnel syndrome 30.99 14.95 9 21577 540 110567173
Balance disorder 30.36 14.95 69 21517 116491 110451222
Mania 30.15 14.95 28 21558 20768 110546945
Device dislocation 30.13 14.95 34 21552 31670 110536043
Depressed level of consciousness 29.84 14.95 67 21519 112211 110455502
Wound 29.73 14.95 5 21581 234432 110333281
Stoma site irritation 29.63 14.95 8 21578 367 110567346
Stoma site inflammation 29.22 14.95 10 21576 1025 110566688
Arthropathy 28.92 14.95 10 21576 287512 110280201
Parkinsonian gait 28.88 14.95 10 21576 1062 110566651
Mitral valve incompetence 28.75 14.95 34 21552 33295 110534418
Saliva discolouration 28.70 14.95 6 21580 89 110567624
Abnormal dreams 28.40 14.95 22 21564 12758 110554955
Asthma 28.30 14.95 7 21579 250284 110317429
Hyperthermia 27.71 14.95 27 21559 21245 110546468
Hypersensitivity 27.59 14.95 23 21563 403975 110163738
Autonomic nervous system imbalance 27.57 14.95 16 21570 5764 110561949
Nasopharyngitis 27.49 14.95 22 21564 394339 110173374
Arthralgia 27.20 14.95 71 21515 779561 109788152
Infection 26.80 14.95 19 21567 362181 110205532
Obsessive-compulsive personality disorder 26.51 14.95 6 21580 131 110567582
Urinary retention 26.16 14.95 48 21538 69635 110498078
Extrapyramidal disorder 25.82 14.95 30 21556 28837 110538876
Purpura senile 25.72 14.95 8 21578 607 110567106
Fatigue 25.29 14.95 137 21449 1215821 109351892
Anxiety 24.94 14.95 133 21453 344945 110222768
Abdominal tenderness 24.58 14.95 20 21566 12437 110555276
Eczema eyelids 24.10 14.95 7 21579 420 110567293
Retroperitoneal fibrosis 24.05 14.95 8 21578 752 110566961
Chorea 23.97 14.95 12 21574 3223 110564490
Wheezing 23.80 14.95 10 21576 255220 110312493
Supine hypertension 23.72 14.95 7 21579 444 110567269
Stoma site reaction 23.53 14.95 7 21579 457 110567256
Sleep attacks 23.39 14.95 6 21580 225 110567488
Drug intolerance 23.31 14.95 27 21559 406485 110161228
Aortic valve sclerosis 23.30 14.95 10 21576 1893 110565820
Psychomotor hyperactivity 23.22 14.95 24 21562 20253 110547460
Choking 23.18 14.95 21 21565 15089 110552624
Device difficult to use 22.89 14.95 23 21563 18782 110548931
Hyperreflexia 22.55 14.95 17 21569 9468 110558245
Ketonuria 22.51 14.95 9 21577 1426 110566287
Salivary hypersecretion 22.49 14.95 22 21564 17399 110550314
Delusion of replacement 22.33 14.95 6 21580 270 110567443
Orthostatic intolerance 22.17 14.95 10 21576 2131 110565582
Granulocytopenia 22.16 14.95 19 21567 12696 110555017
Kleptomania 22.11 14.95 4 21582 26 110567687
Irritable bowel syndrome 21.97 14.95 3 21583 164212 110403501
Resorption bone increased 21.93 14.95 9 21577 1525 110566188
Pyrexia 21.66 14.95 96 21490 898169 109669544
Tension 21.45 14.95 13 21573 5065 110562648
Nocturia 21.08 14.95 21 21565 16969 110550744
Diastolic hypotension 20.96 14.95 6 21580 342 110567371
Product use in unapproved indication 20.39 14.95 35 21551 447342 110120371
Exposure during pregnancy 20.30 14.95 4 21582 167420 110400293
Abdominal pain upper 20.21 14.95 23 21563 349088 110218625
Formication 20.18 14.95 13 21573 5635 110562078
Bladder disorder 20.14 14.95 17 21569 11120 110556593
Catatonia 19.93 14.95 17 21569 11283 110556430
Heat stroke 19.92 14.95 9 21577 1926 110565787
Pancytopenia 19.88 14.95 8 21578 209605 110358108
Product use issue 19.77 14.95 19 21567 311676 110256037
Mental status changes 19.74 14.95 45 21541 76077 110491636
Intentional product use issue 19.69 14.95 12 21574 247894 110319819
Cogwheel rigidity 19.69 14.95 11 21575 3687 110564026
Hallucination, auditory 19.65 14.95 25 21561 26372 110541341
Illusion 19.60 14.95 9 21577 1998 110565715
White blood cell count increased 19.55 14.95 52 21534 96790 110470923
Liver injury 19.53 14.95 3 21583 150410 110417303
Bradyphrenia 19.38 14.95 17 21569 11711 110556002
Neutropenia 19.27 14.95 27 21559 374593 110193120
Device occlusion 19.27 14.95 19 21567 15166 110552547
Discomfort 19.09 14.95 9 21577 214698 110353015
Product physical issue 19.01 14.95 12 21574 5024 110562689
Marital problem 18.99 14.95 5 21581 208 110567505
Loss of consciousness 18.75 14.95 82 21504 196224 110371489
Mesenteric artery thrombosis 18.58 14.95 7 21579 946 110566767
Yawning 18.52 14.95 8 21578 1539 110566174
Sudden death 17.99 14.95 23 21563 24372 110543341
Motor dysfunction 17.98 14.95 23 21563 24383 110543330
Oral discomfort 17.90 14.95 16 21570 11295 110556418
Impaired healing 17.87 14.95 8 21578 196709 110371004
Mitral valve disease 17.72 14.95 10 21576 3415 110564298
Psoriasis 17.71 14.95 3 21583 139990 110427723
Stoma site hypergranulation 17.70 14.95 6 21580 598 110567115
Labelled drug-disease interaction issue 17.64 14.95 4 21582 88 110567625
Medical device site scab 17.61 14.95 3 21583 13 110567700
Product packaging difficult to open 17.60 14.95 4 21582 89 110567624
Libido increased 17.59 14.95 9 21577 2530 110565183
Electrocardiogram J wave 17.43 14.95 4 21582 93 110567620
Vestibular disorder 17.29 14.95 9 21577 2623 110565090
Micturition disorder 17.25 14.95 11 21575 4687 110563026
Migraine 17.20 14.95 6 21580 171646 110396067
Platelet count decreased 17.15 14.95 12 21574 230431 110337282
Ballismus 17.05 14.95 5 21581 310 110567403
Nuchal rigidity 16.84 14.95 7 21579 1225 110566488
Coronary artery dissection 16.75 14.95 7 21579 1241 110566472
Starvation ketoacidosis 16.71 14.95 5 21581 333 110567380
Dermatillomania 16.69 14.95 5 21581 334 110567379
Gallbladder necrosis 16.62 14.95 4 21582 115 110567598
Femoral neck fracture 16.46 14.95 16 21570 12551 110555162
Dehydration 16.43 14.95 102 21484 279409 110288304
Panic attack 16.38 14.95 24 21562 28916 110538797
Stoma site odour 16.27 14.95 4 21582 126 110567587
Paraesthesia 16.24 14.95 18 21568 276503 110291210
Malignant neoplasm progression 16.01 14.95 7 21579 174560 110393153
Musculoskeletal pain 15.77 14.95 8 21578 183015 110384698
Ammonia increased 15.76 14.95 13 21573 8237 110559476
Wrong technique in device usage process 15.59 14.95 12 21574 6889 110560824
Blister 15.44 14.95 13 21573 227363 110340350
Soft tissue mass 15.37 14.95 7 21579 1526 110566187
Dysstasia 15.36 14.95 25 21561 32961 110534752
Rhabdomyolysis 15.29 14.95 55 21531 120346 110447367
Hypomania 15.29 14.95 14 21572 10196 110557517
Treatment failure 15.26 14.95 19 21567 277215 110290498
Therapeutic product effect delayed 15.25 14.95 10 21576 4469 110563244
Listless 15.17 14.95 10 21576 4505 110563208
Influenza 15.17 14.95 7 21579 169094 110398619
Gastrointestinal disorder 15.05 14.95 15 21571 241937 110325776
Tricuspid valve disease 15.00 14.95 5 21581 473 110567240
Injection site pain 15 14.95 8 21578 177914 110389799

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BA01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopa and dopa derivatives
ATC N04BA02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopa and dopa derivatives
ATC N04BA03 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopa and dopa derivatives
FDA CS M0003647 Catecholamines
FDA CS M0370111 Amino Acids, Aromatic
FDA EPC N0000175570 Catecholamine
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D020011 Protective Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D018726 Anti-Dyskinesia Agents
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35522 ฮฒ-adrenergic agonist
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:38147 cardiotonic drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77746 human metabolite
FDA EPC N0000193220 Aromatic Amino Acid

Related Drugs by ATC class:

N04BA Dopa and dopa derivatives 3 drugs
etilevodopafoslevodopamelevodopa

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinsonism indication 32798002
Parkinson's disease indication 49049000 DOID:14330
Restless legs off-label use 32914008 DOID:0050425
Age-related macular degeneration off-label use 267718000 DOID:10871
Suicidal thoughts contraindication 6471006
Hallucinations contraindication 7011001
Dyskinesia contraindication 9748009
Peptic ulcer contraindication 13200003 DOID:750
Disorder of lung contraindication 19829001 DOID:850
Myocardial infarction contraindication 22298006 DOID:5844
Orthostatic hypotension contraindication 28651003
Obstruction of bile duct contraindication 30144000
Depressive disorder contraindication 35489007
Conduction disorder of the heart contraindication 44808001
Duodenal ulcer disease contraindication 51868009 DOID:1724
Diarrhea contraindication 62315008
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Psychoneurotic personality disorder contraindication 268634009
Malignant melanoma contraindication 372244006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.31 acidic
pKa2 9.07 acidic
pKa3 13.05 acidic
pKa4 10.01 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
42MG INBRIJA MERZ N209184 Dec. 21, 2018 RX POWDER INHALATION RE43711 Feb. 3, 2029 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
42MG INBRIJA MERZ N209184 Dec. 21, 2018 RX POWDER INHALATION 12458615 Oct. 21, 2033 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10098845 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10292935 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10688058 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10973769 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10987313 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11666538 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12128141 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12178919 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10098845 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10292935 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10688058 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10973769 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10987313 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11666538 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12128141 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12178919 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10098845 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10292935 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10688058 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10973769 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10987313 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11666538 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12128141 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12178919 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10098845 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10292935 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10688058 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10973769 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 10987313 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11666538 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12128141 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12178919 Oct. 7, 2034 TREATMENT OF PARKINSONS DISEASE
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11033521 March 28, 2039 METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPAโ€”25 MG/LEVODOPAโ€”100 MG
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11033521 March 28, 2039 METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPAโ€”25 MG/LEVODOPAโ€”100 MG, EACH SEGMENT HAVING CARBIDOPAโ€”6.25 MG/LEVODOPAโ€”25 MG
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11033521 March 28, 2039 TREATMENT OF PARKINSONS DISEASE
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11439613 March 28, 2039 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11819485 March 28, 2039 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11986449 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12194150 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11986449 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12194150 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11986449 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12194150 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 11986449 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12109185 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12194150 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12201596 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263148 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12263149 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12295931 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303481 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12303482 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12370163 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12447139 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12453710 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF PARKINSONS DISEASE
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL 12458616 Dec. 21, 2041 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
35MG;140MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 7, 2027 NEW PRODUCT
52.5MG;210MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 7, 2027 NEW PRODUCT
70MG;280MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 7, 2027 NEW PRODUCT
87.5MG;350MG CREXONT IMPAX N217186 Aug. 7, 2024 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 7, 2027 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(1A) dopamine receptor GPCR AGONIST WOMBAT-PK SCIENTIFIC LITERATURE
D(2) dopamine receptor GPCR AGONIST WOMBAT-PK SCIENTIFIC LITERATURE
Tyrosine-protein kinase Lck Kinase IC50 5.43 DRUG MATRIX
Large neutral amino acids transporter small subunit 1 Transporter IC50 4 CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.67 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.54 DRUG MATRIX
Arachidonate 15-lipoxygenase Enzyme IC50 5.65 DRUG MATRIX

External reference:

IDSource
4017790 VUID
N0000146151 NUI
D00059 KEGG_DRUG
4017790 VANDF
4019733 VANDF
C0023570 UMLSCUI
CHEBI:15765 CHEBI
TY3 PDB_CHEM_ID
LDP PDB_CHEM_ID
CHEMBL1009 ChEMBL_ID
DB01235 DRUGBANK_ID
D007980 MESH_DESCRIPTOR_UI
6047 PUBCHEM_CID
3639 IUPHAR_LIGAND_ID
2651 INN_ID
46627O600J UNII
3628 RXNORM
1804 MMSL
4971 MMSL
6641 MMSL
d00216 MMSL
d00277 MMSL
001639 NDDF
004721 NDDF
15383004 SNOMEDCT_US
387086006 SNOMEDCT_US
412383006 SNOMEDCT_US
59187003 SNOMEDCT_US
65955006 SNOMEDCT_US
D004295 MESH_DESCRIPTOR_UI
C0013030 UMLSCUI
DB00988 DRUGBANK_ID
681 PUBCHEM_CID
2417 INN_ID
D004298 MESH_DESCRIPTOR_UI
CHEBI:18243 CHEBI
46627O600J INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Duopa HUMAN PRESCRIPTION DRUG LABEL 2 0074-3012 SUSPENSION 20 mg ENTERAL NDA 31 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0093-9701 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0093-9702 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0093-9703 TABLET 250 mg ORAL ANDA 11 sections
Inbrija HUMAN PRESCRIPTION DRUG LABEL 1 0259-6142 CAPSULE 42 mg RESPIRATORY (INHALATION) NDA 29 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0378-0088 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0378-0094 TABLET, EXTENDED RELEASE 200 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0615-8460 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 27 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0615-8461 TABLET, EXTENDED RELEASE 200 mg ORAL ANDA 27 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0615-8516 TABLET 250 mg ORAL ANDA 25 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0615-8536 TABLET 100 mg ORAL ANDA 25 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0615-8555 TABLET 100 mg ORAL ANDA 25 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5613 TABLET, FILM COATED 50 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5625 TABLET, FILM COATED 75 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5637 TABLET, FILM COATED 100 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5641 TABLET, FILM COATED 125 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5654 TABLET, FILM COATED 150 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5669 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0904-7501 TABLET 100 mg ORAL ANDA 25 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0904-7549 TABLET 250 mg ORAL ANDA 25 sections
Inbrija HUMAN PRESCRIPTION DRUG LABEL 1 10144-342 CAPSULE 42 mg RESPIRATORY (INHALATION) NDA 29 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 16571-157 TABLET, ORALLY DISINTEGRATING 100 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 16571-158 TABLET, ORALLY DISINTEGRATING 100 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 16571-159 TABLET, ORALLY DISINTEGRATING 250 mg ORAL ANDA 24 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-689 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-690 TABLET, FILM COATED 75 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-691 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-692 TABLET, FILM COATED 125 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-693 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-694 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections